- Open
- 6.50
- High
- 6.66
- Low
- 6.00
- Close
- 6.39
- Change
- -0.82 (-12.02%)
- Volume
- 108,700
| 30 Jun 2026 | 07:00:06 | Vesting of Options under Long-Term Incentive Plan |
| 15 Jun 2026 | 07:00:12 | Long Term Incentive Awards |
| 12 Jun 2026 | 07:00:06 | Allergy Therapeutics to present at EAACI 2026 |
| 31 Mar 2026 | 07:00:07 | Interim Results for six months ended 31 Dec 2025 |
| 12 Mar 2026 | 07:00:12 | PDMR Dealings & Shareholding Update |
| 4 Jan 2026 | Annual Report and Accounts (to 2025-06-30) | |
| 19 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 7 Mar 2024 | Annual Report and Accounts (to 2023-06-30) |
Our company is a trailblazing leader in the field of immunology, specializing in the creation and advancement of treatments for allergies.
| 30 Jun 2026 | 07:00:06 | Vesting of Options under Long-Term Incentive Plan |
| 15 Jun 2026 | 07:00:12 | Long Term Incentive Awards |
| 12 Jun 2026 | 07:00:06 | Allergy Therapeutics to present at EAACI 2026 |
| 31 Mar 2026 | 07:00:07 | Interim Results for six months ended 31 Dec 2025 |
| 12 Mar 2026 | 07:00:12 | PDMR Dealings & Shareholding Update |
| 4 Jan 2026 | Annual Report and Accounts (to 2025-06-30) | |
| 19 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 7 Mar 2024 | Annual Report and Accounts (to 2023-06-30) |
Our company is a trailblazing leader in the field of immunology, specializing in the creation and advancement of treatments for allergies.
| 31 Mar 2026 |
| Allergy Therapeutics targets accelerating Grassmuno sales as peanut vaccine advances to next trial phase |
| 4 Mar 2026 | AIM movers: GM terminates Surface transforms order and positive peanut treatment news from Allergy Therapeutics |
| 26 Feb 2026 | Allergy Therapeutics reports positive data across grass pollen and peanut allergy programmes |
| 20 Jul 2020 | Record sales and a COVID-19 wildcard |
| 9 Mar 2020 | Consistent first-half revenue growth |
| 16 Jan 2020 | Sales growth well above market average |
| 31 Mar 2026 |
| Allergy Therapeutics targets accelerating Grassmuno sales as peanut vaccine advances to next trial phase |
| 4 Mar 2026 | AIM movers: GM terminates Surface transforms order and positive peanut treatment news from Allergy Therapeutics |
| 26 Feb 2026 | Allergy Therapeutics reports positive data across grass pollen and peanut allergy programmes |
| 20 Jul 2020 | Record sales and a COVID-19 wildcard |
| 9 Mar 2020 | Consistent first-half revenue growth |
| 16 Jan 2020 | Sales growth well above market average |
